Advertisement
Organisation › Details
Poxel S.A. (Euronext: POXEL)
Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel’s first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin’s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. *
Start | 2009-03-11 splitoff | |
Group | Poxel (Group) | |
Predecessor | Merck Serono (division of Merck KGaA) | |
Industry | imeglimin | |
Industry 2 | PXL770 (Poxel) | |
Person | Kuhn, Thomas (Poxel 200904– CEO) | |
Person 2 | Malgouyres, Pascale (Poxel 200904– Business Development Director) | |
Region | Lyon | |
Country | France | |
Street | 200 avenue Jean Jaurès | |
City | 69007 Lyon | |
Tel | +33-4-3737-2012 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | B: 11 to 50 (2014-11-08) |
Currency | EUR | |
Cash | 42,400,000 (2015-12-31) | |
* Document for »About Section«: Poxel S.A.. (11/5/19). "Press Release: Poxel Obtains Additional Funding to Advance Pipeline Programs. Financing of up to EUR 30 Million through a Bond Loan with IPF Partners". Lyon. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Poxel (Group)
- [1] Poxel S.A.. (5/25/20). "Press Release: Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases". Lyon....
- [2] Poxel S.A.. (5/25/20). "Press Release: Poxel Successfully Raises €17.7 Million in a Capital Increase [Not for US, AU, CA or JP]". Lyon....
- [3] Poxel S.A.. (11/5/19). "Press Release: Poxel Obtains Additional Funding to Advance Pipeline Programs. Financing of up to EUR 30 Million through a Bond Loan with IPF Partners". Lyon....
- [4] Artios Pharma Ltd.. (2/26/18). "Press Release: Artios Pharma Appoints Pierre Legault as Chairman of its Board of Directors". Cambridge....
- [5] Poxel S.A.. (4/25/17). "Press Release: Poxel Announces Appointment of Anne Renevot as Chief Financial Officer". Lyon....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top